• Akhtar M, Elliott P. The genetics of hypertrophic cardiomyopathy. Glob Cardiol Sci Pract 2018. 2018;3:36. https://doi.org/10.21542/gcsp.2018.36.

    Article 

    Google Scholar
     

  • Alfares AA, Kelly MA, McDermott G, Funke BH, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880–8. https://doi.org/10.1038/gim.2014.205.

    Article 
    PubMed 

    Google Scholar
     

  • Arad M, Maron BJ, Gorham JM, Johnson WH Jr, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352(4):362–72. https://doi.org/10.1056/NEJMoa033349.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Auray-Blais C, Lavoie P, Boutin M, et al. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. ClinChimActa. 2017;466:185–93.

    CAS 

    Google Scholar
     

  • Balendran S, Oliva P, Sansen S, Mechtler TP, et al. Diagnostic strategy for females suspected of Fabry disease. Clin Genet. 2020;97(4):655–60. https://doi.org/10.1111/cge.13694.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Bevilacqua J, Guecaimburu E, Perna A, et al. The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease. Orphanet J Rare Dis. 2020;15(1):11.

    Article 

    Google Scholar
     

  • Biegstraaten M, Arngrímsson R, Barbey F, Boks L, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. https://doi.org/10.1186/s13023-015-0253-6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30:2114–20.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bonaventura J, Norambuena P, Votýpka P, Hnátová H, et al. Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background. Cardiovasc Diagn Ther. 2020;10(2):193–200. https://doi.org/10.21037/cdt.2020.01.12.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Brady RO, Gal AE, Bradley RM, Martensson E, et al. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase Deficiency N Engl J Med. 1967;276(21):1163–7. https://doi.org/10.1056/NEJM196705252762101.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Brady M, Montgomery E, Brennan P, Mohindra R, Sayer JA. Diagnosing Fabry disease–delays and difficulties within discordant siblings. QJM. 2015;108(7):585–90. https://doi.org/10.1093/qjmed/hct024.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110:1047–53.

    CAS 
    Article 

    Google Scholar
     

  • Clinical Guidelines. Hypertrophic cardiomyopathy. Moscow, 2020. https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Kardiomiopatiya.pdf. (in Russ.)

  • Desnick RJ, Ioannou YA, Eng CM. A-galactosidase a deficiency: Fabry disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, editors. The online metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2014.


    Google Scholar
     

  • Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995–2017. J Med Genet. 2018;55:261–8. https://doi.org/10.1136/jmedgenet-2017-105080.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Duro G, Zizzo C, Cammarata G, Burlina A, et al. Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci. 2018;19(12):3726. https://doi.org/10.3390/ijms19123726.

    CAS 
    Article 
    PubMed Central 

    Google Scholar
     

  • Elleder M, Bradová V, Smíd F, Budĕsínský M, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry’s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449–55. https://doi.org/10.1007/BF01606034.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Elliott P, Baker R, Pasquale F, Quarta G, et al. ACES study group. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 2011;97(23):1957–60. https://doi.org/10.1136/heartjnl-2011-300364.

    Article 
    PubMed 

    Google Scholar
     

  • Erdogmus S, Kutlay S, Kumru G, Ors Sendogan D, et al. Fabry disease screening in patients with kidney transplant: a single-center study in Turkey. Exp Clin Transplant. 2020;18(4):444–9. https://doi.org/10.6002/ect.2019.0279.

    Article 
    PubMed 

    Google Scholar
     

  • Gaggl M, Lajic N, Heinze G, et al. Screening for Fabry disease by urinary globotriaosylceramide isoforms measurement in patients with left ventricular hypertrophy. Int J Med Sci. 2016;13:340–6.

    Article 

    Google Scholar
     

  • Hagège AA, Caudron E. Damy T et al Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart. 2011;97:131–6.

    Article 

    Google Scholar
     

  • Hauth L, Kerstens J, Yperzeele L, Eyskens F, et al. Galactosidase alpha p.A143T variant Fabry disease may result in a phenotype with multifocal microvascular cerebral involvement at a young age. Front Neurol. 2018;9:336. https://doi.org/10.3389/fneur.2018.00336.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Havndrup O, Christiansen M, Stoevring B, et al. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail. 2010;12:535–40. https://doi.org/10.1093/eurjhf/hfq073.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Hsu TR, Sung SH, Chang FP, Yang CF, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A). Orphanet J Rare Dis. 2014;9:96. https://doi.org/10.1186/1750-1172-9-96.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Johnson K, Töpf A, Bertoli M, et al. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. Orphanet J Rare Dis. 2017;12:173. https://doi.org/10.1186/s13023-017-0722-1.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kampmann C, Linhart A, Baehner F, Palecek T, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008;130(3):367–73. https://doi.org/10.1016/j.ijcard.2008.03.007.

    Article 
    PubMed 

    Google Scholar
     

  • Kim WS, Kim HS, Shin J, et al. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy. J Korean Med Sci. 2019;34(7): e63. https://doi.org/10.3346/jkms.2019.34.e63.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kuzenkova LM, Namazova-Baranova LS, Podkletnova TV, Gevorkyan AK, et al. Fabry disease: symptoms in children and teenagers. Voprosy Sovremennoj Pediatrii. 2015;14(3):341–8. https://doi.org/10.15690/vsp.v14i3.1369.

    Article 

    Google Scholar
     

  • Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, et al. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11(1):54. https://doi.org/10.1186/s13023-016-0441-z.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013. arXiv: 1303.3997v2 [q-bio.GN].

  • Lin HY, Chong KW, Hsu JH, Yu HC, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450–6. https://doi.org/10.1161/CIRCGENETICS.109.862920.

    Article 
    PubMed 

    Google Scholar
     

  • Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28:1228–35.

    Article 

    Google Scholar
     

  • Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, et al. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant. 2003;18(8):1581–4. https://doi.org/10.1093/ndt/gfg194.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Lukas J, Giese AK, Markoff A, Grittner U, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genet. 2013;9(8):e1003632. https://doi.org/10.1371/journal.pgen.1003632.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–70. https://doi.org/10.1161/CIRCRESAHA.117.311059.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21:44–52.

    Article 

    Google Scholar
     

  • Mazzarotto F, Olivotto I, Boschi B, Girolami F, et al. Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a new era in clinical testing? J Am Heart Assoc. 2020;9(8): e015473. https://doi.org/10.1161/JAHA.119.015473.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Moiseev S, Fomin V, Savostyanov K, Pushkov A, et al. The prevalence and clinical features of Fabry disease in hemodialysis patients: Russian nationwide Fabry dialysis screening. Nephron. 2019;141(4):249–55. https://doi.org/10.1159/000495886.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Namazova-Baranova LS, Baranov AA, Pushkov AA, Savostyanov KV. Fabry disease in children: a federal screening programme in Russia. Eur J Pediatr. 2017;176(10):1385–91.

    Article 

    Google Scholar
     

  • Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7(1):8–16. https://doi.org/10.1161/CIRCGENETICS.113.000249.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Oder D, Vergho D, Ertl G, Wanner C, Nordbeck P. Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles. BMC Med Genet. 2016;17(1):46. https://doi.org/10.1186/s12881-016-0309-z.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Riera C, Lois S, Domínguez C, Fernandez-Cadenas I, et al. Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations. Proteins. 2015;83(1):91–104. https://doi.org/10.1002/prot.24708.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Ruiz-Salas A, García-Pinilla JM, Cabrera-Bueno F, Fernández-Pastor J, et al. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773–7. https://doi.org/10.1093/europace/euv079.

    Article 
    PubMed 

    Google Scholar
     

  • Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105:1407–11.

    CAS 
    Article 

    Google Scholar
     

  • Sadasivan C, Chow JTY, Sheng B, Chan DKH, et al. Screening for Fabry disease in patients with unexplained left ventricular hypertrophy. PLoS ONE. 2020;15(9): e0239675. https://doi.org/10.1371/journal.pone.0239675.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sagnelli A, Savoiardo M, Marchesi C, Morandi L, et al. Adult polyglucosan body disease in a patient originally diagnosed with Fabry’s disease. Neuromuscul Disord. 2014;24(3):272–6. https://doi.org/10.1016/j.nmd.2013.11.006.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47(5):784–9.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Savostyanov KV, Namazova-Baranova LS, Basargina EN, Vashakmadze ND, et al. The new genome variants in Russian children with genetically determined cardiomyopathies revealed with massive parallel sequencing. Ann Russ Acad Med Sci. 2017;72(4):242–53. https://doi.org/10.15690/vramn872.

    Article 

    Google Scholar
     

  • Savostyanov K, Pushkov A, Mazanova N, Pak L, Kuzenkova L, Podkletnova T, Pakhomov A, Sukhozhenko A, Moiseev S. Lyso-Gb3 is as a primary biomarker for fabry disease screening among high-risk contingents. Mol Genet Metab. 2019;126(2):S130–1.


    Google Scholar
     

  • Schiffmann R, Swift C, McNeill N, et al. Low frequency of Fabry disease in patients with common heart disease. Genet Med. 2018;20:754–9. https://doi.org/10.1038/gim.2017.175.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, et al. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015;52(4):262–8. https://doi.org/10.1136/jmedgenet-2014-102872.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31–40. https://doi.org/10.1086/504601.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death. World J Cardiol. 2010;2(9):289–98. https://doi.org/10.4330/wjc.v2.i9.289.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sulaiman H, Finegan E, Tisdall RA, Murphy R. Prevalence of Fabry disease among patients diagnosed hypertrophic cardiomyopathy and unexplained left ventricular hypertrophy in St. James hospital (2013–2015). Heart. 2016;102(Suppl 9):A34.


    Google Scholar
     

  • van der Tol L, Smid BE, Poorthuis BJ, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1–9. https://doi.org/10.1136/jmedgenet-2013-101857.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Valtola K, Nino-Quintero J, Hedman M, Lottonen-Raikaslehto L, et al. Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase Agene. Heart. 2020;106(8):609–15. https://doi.org/10.1136/heartjnl-2019-315933.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Xiao Y, Sun Y, Tian T, Wang TJ, et al. Prevalence and clinical characteristics of Fabry disease in Chinese patients with hypertrophic cardiomyopathy. Am J Med Sci. 2021;362(3):260–7. https://doi.org/10.1016/j.amjms.2021.01.009.

    Article 
    PubMed 

    Google Scholar
     

  • Yamamoto S, Nagasawa T, Sugimura K, Kanno A, et al. Clinical diversity in patients with Anderson-Fabry disease with the R301Q mutation. Intern Med. 2019;58:603–7. https://doi.org/10.2169/internalmedicine.0959-18.

    Article 
    PubMed 

    Google Scholar
     

  • Yogasundaram H, Kim D, Oudit O, Thompson RB, Weidemann F, Oudit GY. Clinical features, diagnosis, and management of patients with anderson-fabry cardiomyopathy. Can J Cardiol. 2017;33(88):3–897. https://doi.org/10.1016/j.cjca.2017.04.015.

    Article 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)